Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | OGT | O15294 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 13/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31686101 | 1.00 | MCL1 (0.49) | MCL1OGTGRM5EPHX2PARP1 | |
| SCHEMBL1137634 | 0.76 | PSMB8 (0.61) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL30146353 | 0.76 | PSMB8 (0.61) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL1853002 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL3043379 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL5077255 | 0.76 | PSMB8 (0.61) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL1285749 | 0.76 | EPHX2 (0.50) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL5540274 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL8223813 | 0.76 | PSMB8 (0.61) | PARP1POLBTDP1 | |
| SCHEMBL7503486 | 0.76 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | claimed |
| JP-61043188-A | — | — | None | — | — | JP | disclosed |
| CN-115154470-B | Methods of treating depression using orexin-2 receptor antagonists | 詹森药业有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-108883110-B | Methods of treating depression using orexin-2 receptor antagonists | 詹森药业有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110156712-A | It is a kind of to utilize aromatic nitration by-product synthesis benzoxazoles class compound and application | 邵玉田 | 2019-08-23 | — | — | CN | disclosed |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | SERENTRIX, LLC | 2019-03-19 | — | — | US | disclosed |
| EP-2552888-B1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | SERENTRIX LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX, LLC | 2017-06-01 | — | — | US | disclosed |
| EP-0045892-B1 | PROCESS FOR THE PREPARATION OF PRECURSORS FOR POLYMERS CONTAINING THE OXAZOLIN-2-ONE RING, AND THEIR USE IN THE PRODUCTION OF HIGH MOLECULAR WEIGHT POLYMERS | BAYER AG (DE) | 1984-02-01 | — | — | EP | disclosed |
| EP-0050780-B1 | ISOCYANATO-OXAZOLINONES, METHOD FOR THE PREPARATION OF OXAZOLIDIN-2-ONE RINGS CONTAINING PLASTICS PRECURSORS, AND THEIR USE IN THE PREPARATION OF HIGH-MOLECULAR PLASTICS | BAYER AG (DE) | 1983-12-28 | — | — | EP | disclosed |
| US-4350781-A | Process for the preparation of polymer precursors containing oxazolin-2-one rings | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-21 | — | — | US | disclosed |
| EP-0050780-A1 | Isocyanato-oxazolinones, method for the preparation of oxazolidin-2-one rings containing plastics precursors, and their use in the preparation of high-molecular plastics | BAYER AG (DE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0045892-A1 | Process for the preparation of precursors for polymers containing the oxazolin-2-one ring, and their use in the production of high molecular weight polymers | BAYER AG (DE) | 1982-02-17 | — | — | EP | disclosed |
| EP-0000737-B1 | MONOAZO PIGMENTS OF THE ACETOACETYLAMINO BENZIMIDAZOLONE SERIES, THEIR PREPARATION AND THEIR USE FOR COLOURING ORGANIC MATERIAL OF HIGH MOLECULAR WEIGHT | CIBA-GEIGY AG (CH) | 1981-04-29 | — | — | EP | disclosed |
| US-4191703-A | REACTING 5- OR 6-(HYDROXYETHYL SULFONYL) BENZOXAZOL-2- ONE WITH SULFURIC ACID AND/OR SULFUR TRIOXIDE WHILE KNEADING | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| EP-0000737-A1 | Monoazo pigments of the acetoacetylamino benzimidazolone series, their preparation and their use for colouring organic material of high molecular weight | CIBA-GEIGY AG (CH) | 1979-02-21 | — | — | EP | disclosed |
| US-4012371-A | Benzinaldazolyl-, quinolonyl-, or phenmorpholonylazo-3-cyano-4-methyl-1,2-[1',2']-benz-[4',5']-imidazolo-6-hydroxypyridine colorants | CIBA-GEIGY CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
| JP-S06143188-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MCL1 37/4885OGT 4237/4885GRM5 3790/4885 |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | MCL1 4480/4885OGT 2448/4885GRM5 268/4885 |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | TRPV1, TRPV5, TRPV3 | MCL1 4480/4885OGT 2448/4885GRM5 268/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MCL1 3068/4885OGT 2566/4885GRM5 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.